Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate Certara, Inc. before investing.

In this article, we go over a few key elements for understanding Certara, Inc.’s stock price such as:

• Certara, Inc.’s current stock price and volume
• Why Certara, Inc.’s stock price changed recently
• Upgrades and downgrades for CERT from analysts
• CERT’s stock price momentum as measured by its relative strength

About Certara, Inc. (CERT)

Before we jump into Certara, Inc.’s stock price, history, target price and what caused it to recently rise, let’s take a look at some background.

Certara, Inc., together with its subsidiaries, provides technology-driven services and software products for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the Americas, Europe, the Middle East, Africa, and Asia Pacific. It offers model-informed drug development solutions; biosimulation solutions to predict pharmacokinetics and pharmacodynamics; Simcyp simulator, a mechanistic biosimulation platform for physiologically based pharmacokinetic simulation; Simcyp Discovery for scientists working on pre-investigational new drug and translational stages; Simcyp Biopharmaceutics for formulation scientists; and Simcyp Secondary Intelligence that integrates toxicology with quantitative analysis of large networks of molecular and functional biological changes. It also provides Phoenix WinNonlin, a platform for non-compartmental analysis; Phoenix cloud that offers a secured and validated Certara Amazon Web Services workspace; Phoenix NLME, a population modeling and simulation software; and Pirana Modeling Workbench, which provides modelers with a structure to facilitate the iterative processes. In addition, it offers Chemaxon JChem engines, a chemical search engine; Chemaxon Compound Registration that supports a streamlined lead optimization process workflow; Chemaxon Design Hub, a design and tracking platform; Certara D360 software, a scientific informatics system; and Chemaxon Marvin, a chemical drawing tool. Further, the company provides pinnacle 21, a cloud-based platform for clinical data automation, standardization, and validation; Pinnacle 21 Data Exchange to define data standards and specifications; Metadata Repository that enables study design using controlled and standardized data; CoAuthor software, which creates and writes regulatory submissions and medical publications; and GlobalSubmit, a submissions management software. Certara Inc. was founded in 2008 and is headquartered in Radnor, Pennsylvania.

Want to learn more about Certara, Inc.’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about Certara, Inc..

Certara, Inc.’s Stock Price as of Market Close

As of May 21, 2026, 2:16 PM, CST, Certara, Inc.’s stock price was $5.095.

Certara, Inc. is up 9.1% from its previous closing price of $4.670.

During the last market session, Certara, Inc.’s stock traded between $4.570 and $5.120. Currently, there are approximately 157.75 million shares outstanding for Certara, Inc..

Certara, Inc.’s trailing earnings per share are negative, so the stock does not have a meaningful P/E ratio. We suggest investors evaluate other financial metrics to understand its overall valuation.

Certara, Inc. Stock Price History

Certara, Inc.’s (CERT) price is currently down 16.88% so far this month.

During the month of May, Certara, Inc.’s stock price has reached a high of $6.460 and a low of $4.450.

Over the last year, Certara, Inc. has hit prices as high as $13.880 and as low as $4.450. Year to date, Certara, Inc.’s stock is down 42.17%.

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

What Caused Certara, Inc. Stock’s Price to Rise?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. As of May 20, 2026, there was 1 analyst who downgraded Certara, Inc.’s stock and 0 analysts who upgraded over the last month.

Additionally, you'll want to evaluate Certara, Inc.’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on Certara, Inc.’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

Certara, Inc.’s current valuation based on AAII’s Value Grade is a B, which means it is considered to be Value.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about Certara, Inc. (CERT) by visiting AAII Stock Evaluator.

Relative Price Strength of Certara, Inc.

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of May 20, 2026, Certara, Inc. has a weighted four-quarter relative price strength of -26.20%, which translates to a Momentum Score of 7 and is considered to be Very Weak.

Want to learn more about how Certara, Inc. is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

Certara, Inc. Stock Price: Bottom Line

As of May 21, 2026, Certara, Inc.’s stock price is $5.095, which is up 9.1% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like Certara, Inc. stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.